A bill to amend the Pharmaceutical and Medical Devices (PMD) Law is expected to be submitted to the ordinary session of the Diet this year, which was convened on January 17 for a 150-day run. The proposed amendment is for…
HOME > COMMENTARY
COMMENTARY
- Hardships and Successes of Diversified Entrants Lead to Question: Will Pharmaceuticals Continue to Be a Growth Sector?
March 5, 2014
- Revised JCS Guidelines Clarify Role of Novel Oral Anticoagulants in Patients with Atrial Fibrillation
February 12, 2014
- Will JPWA’s Move to Integrate Tax Display Method Dispel Medical Institutions’ Misconception?
January 31, 2014
- FY2014 May Be Year 1 of New Reform Era; Drug Makers Need to “Turn Calamity into Good Fortune”
January 7, 2014
- First SGLT-2 Inhibitor Set to Debut Next April; Curtain Rising on “Unprecedentedly Competitive” Market
December 18, 2013
- Bearing “Edo” in Its Name, Japan-Originated Edoxaban Set to Challenge Rival Anticoagulants in World Market
December 6, 2013
- MHLW Shocks Generic Drug Industry by Proposing “50% Rule,” Expansion of Uniform Pricing
November 19, 2013
- Range of Drugs Eligible for Premium for New Drug Development May Be Reviewed; Industry Needs to Dispel Suspicions
November 13, 2013
- Interim Report of Diovan Committee Raises Further Questions
October 15, 2013
- Remicade Biosimilar Debut Awaited in FY2014; Good Opportunity to Revisit Healthcare Finance?
October 4, 2013
- Comprehensive Review of Package Inserts to Begin with Effort to Identify Inconsistencies Between Inserts for Similar Drugs
August 27, 2013
- Transparency Guidelines Go Live, Will It Help Pharmas Win Public Trust?
August 2, 2013
- Overseas Outlook Will Be Essential to Survival and Progress of Domestic CROs
June 24, 2013
- PMDA’s Seriousness About Becoming a Leading Global Regulatory Authority to Be Tested
May 30, 2013
- Beyond Risk Management: RMPs Provide Opportunity for Post-Marketing Drug Development and Product Differentiation
May 8, 2013
- Iressa Cases Signal Risks Hiding in Daily Clinical Practices
April 22, 2013
- Will Drugs that Fight Cancer Stem Cells Succeed? Domestic Clinical Trial by DSP on the Horizon
March 15, 2013
- Gov’t, Industry to Support Developing Countries through Development of Drugs for Infectious Diseases; Hoping to Secure Future Business Opportunities as Well
February 27, 2013
- What Next for a “Mature” ICH? What More Can Be Done Beyond Regulatory Harmonization?
January 22, 2013
- Hot Products in 2013: New Drugs Likely to Jolt RA Treatment, Anticoagulant Markets
January 8, 2013
ページ
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…
Japan’s all-important reimbursement policy panel on December 22 approved an outline of the next drug pricing reform scheduled for April 2022, which embraces plans to reward innovative new indications and introduce a grace period for so-called “spillover” re-pricing.The reform outline…
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…